Affymetrix Eyeing Tuck-In Acquisitions to Bolster Downstream Market Presence

If the array vendor does decide to buy a company or platform, it will most likely be in the biomarker validation market, where the company sees its future, and not in the next-generation sequencing space.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.